# Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/short-course-adjuvant-trastuzumab-therapy-in-early-stage-breast-cancer-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Timo Purmonen,Emma Pänkäläinen,Juha Turunen,Christian Asseburg,Janne Martikainen |
| Citations | 53 |
| DOI | 10.3109/0284186x.2011.553841 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | https://www.tandfonline.com/doi/pdf/10.3109/0284186X.2011.553841?needAccess=true |
| OpenAlex ID | https://openalex.org/W1985914856 |
| PMID | 21299447 |
| Type | article |
| Year | 2011 |

## Paper authors

- [Christian Asseburg](https://scholariq.org/researchers/christian-asseburg/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.